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CARRS Surveillance study: design and methods to
assess burdens from multiple perspectives
Manisha Nair1, Mohammed K Ali2, Vamadevan S Ajay3, Roopa Shivashankar4, Viswanathan Mohan5,
Rajendra Pradeepa6, Mohan Deepa6, Hassan M Khan7, Muhammad M Kadir7, Zafar A Fatmi7, K Srinath Reddy8,
Nikhil Tandon9, KM Venkat Narayan10 and Dorairaj Prabhakaran4*

Abstract
Background: Cardio-metabolic diseases (CMDs) are a growing public health problem, but data on incidence,
trends, and costs in developing countries is scarce. Comprehensive and standardised surveillance for noncommunicable diseases was recommended at the United Nations High-level meeting in 2011.
Aims: To develop a model surveillance system for CMDs and risk factors that could be adopted for continued
assessment of burdens from multiple perspectives in South-Asian countries.
Methods: Design: Hybrid model with two cross-sectional serial surveys three years apart to monitor trend, with a
three-year prospective follow-up of the first cohort.
Sites: Three urban settings (Chennai and New Delhi in India; Karachi in Pakistan), 4000 participants in each site
stratified by gender and age.
Sampling methodology: Multi-stage cluster random sampling; followed by within-household participant selection
through a combination of Health Information National Trends Study (HINTS) and Kish methods.
Culturally-appropriate and methodologically-relevant data collection instruments were developed to gather
information on CMDs and their risk factors; quality of life, health-care utilisation and costs, along with objective
measures of anthropometric, clinical and biochemical parameters. The cohort follow-up is designed as a pilot study
to understand the feasibility of estimating incidence of risk factors, disease events, morbidity, and mortality.
Results: The overall participant response rate in the first cross-sectional survey was 94.1% (Chennai 92.4%, n = 4943;
Delhi 95.7%, n = 4425; Karachi 94.3%, n = 4016). 51.8% of the participants were females, 61.6% < 45years, 27.5% 45–
60years and 10.9% >60 years.
Discussion: This surveillance model will generate data on prevalence and trends; help study the complex lifecourse patterns of CMDs, and provide a platform for developing and testing interventions and tools for prevention
and control of CMDs in South-Asia. It will also help understanding the challenges and opportunities in establishing
a surveillance system across countries.
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Background
Cardio-metabolic diseases (CMDs) broadly comprise
of diabetes mellitus, cardiovascular diseases (CVD),
chronic kidney disease (CKD) and their common interconnected risk factors such as obesity, insulin resistance,
glucose intolerance, dyslipidaemia, and hypertension.
They are a growing public health problem worldwide [1]
accompanying socioeconomic and nutrition transitions [24]. Coronary heart disease (CHD), cerebrovascular disease,
and diabetes together account for 30% of global mortality
and 80% of these deaths occur in low-and-middle-income
countries (LMICs) [2,5-7]. In 2010, globally, 4,000,000
deaths were due to diabetes, the highest in absolute numbers was (1,008,000) in India [8]. The largest fraction of
deaths from CHD (37%) and stroke (30%) attributable to
high blood glucose were in South-Asia [9]. Further, in
people of South-Asian origin, onset of diabetes [10-12],
other cardio-metabolic risk factors [13,14], and late-stage
disease events [15,16] occur at lower body mass indices and
younger ages than other ethnic groups [16-23].
Key recommendations of the 2011 United Nations
high-level meeting on non-communicable diseases
(NCDs) and the US Institute of Medicine are initiation
and strengthening of surveillance for NCDs [24] and the
creation of integrated, comprehensive, sustainable, ongoing nationwide surveillance systems [25]. In SouthAsia, current efforts are limited to local surveys with
vast state-wise heterogeneity and variable data quality
[26-28]. Furthermore, projections of national income
losses related to CMDs are based on models using
inputs from limited local studies [29]; data on individual
and household costs and social burdens are also scarce
[30]. Current efforts by the Governments of India and
Pakistan in setting up nationwide surveillance of NCDs
are limited to self-reported surveys [31,32]. A robust
surveillance system would need to be representative of
the population of interest, utilise standardised methods
that are not solely reliant on self-reporting, be amenable
to scaling up, would be sustainably financed by the
country/region itself, and also become a platform for
further research opportunities and policy guidance
(much like the role of the Centres for Disease Control
and Prevention [CDC] in the United States) [33,34].
We present the design and methods of a model
surveillance system for CMDs, the CARRS (Centre for
cArdiometabolic Risk Reduction in South-Asia)-Surveillance Study, which could be adopted for continuing
assessments of burdens in South-Asian countries. The
CARRS-Surveillance study builds on the WHO STEPS
(World Health Organisation stepwise Approach to Surveillance) model [35] to capture prevalence of risk factors, CMDs, and their socioeconomic impact in serial
representative surveys to understand trends, but goes a
step further to convert the cross-sectional survey into a
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large, urban, sub-continent wide prospective cohort at
lower-costs, to understand the incidence of risk factors,
diseases, complications, and mortality. Thus, apart from
estimating burdens, it can be used to develop SouthAsian assessment and clinical management systems to
tailor care and preventive approaches.

Methods
Study design

This is a hybrid cohort-modelled cross-sectional multicentre surveillance study to be conducted over a period
of four years. Two cross-sectional surveys conducted
three years apart on standalone representative samples
of each of the three city-wide populations, using objective measures will permit estimation of the prevalence
and trends of CMDs and their risk factors. Those enrolled in the first cross-sectional survey will be followed
as a cohort in a three-year study to estimate (i) the incidence of new risk factors (such as obesity, hypertension,
diabetes,); (ii) incidence of later-stage target organ diseases such as peripheral vascular disease, stroke, myocardial infarction, congestive heart failure, chronic stable
angina, CKD, retinopathy, neuropathy, and amputation;
(iii) assessment of health service utilisation and costs including hospitalisation and outpatient use and (iv) morbidity and mortality associated with CMDs.
The first cross-sectional survey has been completed
with ongoing first year of cohort-follow-up. The survey
was comprehensive, undertaking assessments of quality
of Life (QoL), and socioeconomic burdens on individuals
and families with regards to these diseases. Participants
underwent anthropometric measurements, blood pressure (BP) assessment, and provided biochemical specimens. The cohort follow-up was limited to patient
reports with recording of BP and anthropometry. CMDs
and their complications were diagnosed using standard
definitions and coded using the International Classification of Diseases 10 (ICD-10) codes.
The study sites are metropolitan urban settings with
large, growing (due to continued births and migration from
various parts of the country), and heterogeneous populations. Estimates suggest that population size in Chennai
(4.68 million) [36], Karachi (13 million) [37], and Delhi
(16.3 million) [36], and the diversity in their composition
make these cities current and future archetypes of rapid
socio-economic, demographic, epidemiologic, and nutrition/lifestyle transitions in the South-Asian region.
Sample size estimation

Utilising risk factor prevalence estimates from previously
published Indian and Pakistani studies and anticipating a
response rate of 80% with a design effect factor of 1.5
(to account for cluster sampling), the sample size estimates were generated for males and females in three age
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Table 1 Sample size estimation (per site)
Risk factors

Level of
confidence

Margin
of error

Baseline levels
of indicators

Design
effect

Expected
response
rate

No. of
age/sex
estimates

Sample
size

Tobacco use

1.96

0.05

0.23

1.5

0.8

6

3062

Hypertension

1.96

0.05

0.36

1.5

0.8

6

3983

Diabetes

1.96

0.05

0.15

1.5

0.8

6

2204

Overweight (BMI ≥ 23)

1.96

0.05

0.65

1.5

0.8

6

3933

strata in each urban setting. As shown in table 1, the
highest required sample size (3983 rounded-off to 4000
participants) permits each site to reliably estimate one
or more of the CMD risk factors for each of the gender
and age strata leading to a total sample size of 12,000.
With regards to the cohort follow-up, separate consent
has been taken from participants to be followed up
for three years or longer. An overall 15 - 25% loss-tofollow-up by the 3-year data collection time-period is
anticipated due to the high probability of migration
among the young population for job opportunities,
marriage (in case of females), etc. Retention efforts (in
the form of maintaining updated contact information;
collecting contact details of friends and relatives; periodic reminder calls; courtesy calls/visits) have been put
in place to keep track of participants and minimise
loss-to-follow-up. Although the study at present is not
powered to estimate incidence of CMDs and their risk
factors, it has the potential to determine such incidence rates if the follow-up period is increased and
the study is scaled up by adding follow up of subsequent cross-sectional samples.
Sampling method

Households were selected in each of the three cities using a
multi-stage cluster random sampling technique. Each city
has its own distinctive municipal sub-divisions, encompassing municipal corporations, wards and Census Enumeration Blocks (CEB), which were used sequentially as
sampling frames to randomly select households. While
wards were the primary sampling units (PSUs) for Chennai
and Delhi, CEBs or clusters were the PSUs for Karachi.
STATA version 10.1 (Statacorp, TX) [38] and data from the
most recent census were used to randomly select the
wards, CEBs, and households (defined below.). To give each
household an equal chance of being selected for the study
and to identify households constructed after the last census
survey, manual listing and mapping of all households in
each CEB was done before randomly selecting them.
Two participants, one male and one female, aged
20 years or older, were selected from each household
based on inclusion and exclusion criteria given below.
Two methods were used for within household sampling
– (i) for households with one to two adults (≥20 years),

the sampling strategy described in the 2002 Health Information National Trends Study (HINTS) in the USA
was used [39]. According to HINTS, one or both individuals (one male and one female) were selected and enrolled into the study based on eligibility criteria and
informed consent; (ii) for households with more than
two eligible adults, the “Kish method” used in the
WHO’s STEPS surveys [35] was applied. Recruitment of
participants, and data and specimen collection were conducted through three visits to each participant’s place of
residence, respectively (Visit-0, Visit-1, and Visit-2).

Inclusion and exclusion criteria for CARRS – Surveillance
Study
Inclusion criteria:

Any individual aged ≥20 years and permanently residing
in the selected household.
For the purpose of this study, a permanent resident
was defined as a person living in the selected household,
was related to the household head and ate at least 3
meals in a week with the family.
Households were defined as “a group of people who
live together, usually pool their income and eat at
least one meal together a day when they are at home.
This does not include people who have migrated
permanently or are considered visitors” [(Integrated
Disease Surveillance Project (IDSP)] [31].
Exclusion criteria:
 Pregnant women were not included in the study

since their biochemical parameters would vary from
the normal physiology due to pregnancy, further
their patterns of diet and physical activity would also
be different from usual.
 Bed-ridden individuals were excluded because of the
difficulty in taking anthropometric measurements in
these individuals. However, reasons for being
confined to bed were collected from such
individuals to estimate prevalence of CMDs among
this excluded group (since CMDs can be the cause
for being bed-ridden).
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Table 2 Summary of the surveillance indicators, measures, methods and instruments
Indicators

Measures

Methods

Instruments

Demographic
and Social
Characteristics*

Age / Sex / Marital Status / Religion

Questionnaires

Chennai Urban Population Study (CUPS),
Chennai Urban Rural Epidemiological
Study (CURES), Establishment of Sentinel
Surveillance System for CVD in Indian
Industrial Populations (Sentinel
Surveillance Study)

Education / Income / Occupation

Household assets

Standard of Living Index (SLI)

Contact Details (and supplemental contacts)
Behavioral
risk factors*

Tobacco use

Questionnaire / Cotinine in
saliva (5 % of participants)

Alcohol use

Questionnaire

Dietary habits

Questionnaire/ validation by
24-hour dietary recall in a
sub-sample

INTERHEART Study

Physical activity

Questionnaire

International Physical Activity Questionnaire
(IPAQ)– short

Sleep
Physiological
and biochemical
risk factors**

CUPS, CURES, Sentinel Surveillance Study

Sleep Heart Health Study (SHHS)

Hypertension

Blood pressure measurement

Standardized method (American Heart
Association) and validated instrument
(certified by British Hypertensive Society
and Association for the Advancement of
Medical Instrumentation)

Dyslipidemia

Laboratory estimation of
serum total cholesterol, low
density lipoprotein cholesterol,
very low density lipoprotein
cholesterol, high density
lipoprotein cholesterol,
triglycerides, Apolipoprotein
A and B (not done in Karachi)

Standardized across all three study sites

Obesity

Anthropometry (height /
weight / body circumferences
/ skinfold thickness / body
composition/bio-impedance)

Standard procedures based on National
Health And Nutrition Examination
Survey-III with instruments used in
epidemiological studies on South Asian
population

Diabetes

Laboratory estimation of
fasting plasma glucose,
glycated haemoglobin (HbA1c)

Standardized across all three study sites

Female
Reproductive
history*

Menarche/ gestational history
(pregnancy induced hypertension,
gestational diabetes), menopause
(surgical / physiological / whether on
hormone replacement therapy) /
contraception

Questionnaire

CUPS, CURES, India Health Study (IHS)

Quality of Life*

Mobility, self care, usual activities,
pain/discomfort, anxiety/depression
(related to cardiometabolic diseases;
CMDs and their risk factors)

Questionnaire

European Quality of Life 5 Dimensions
questionnaire (EQ-5D)

Morbidity**

Stroke / Myocardial infarction /
Congestive heart failure / Chronic
stable angina

Questionnaires including
medication history;

Rose Angina, CURES, IHS, Sentinel
Surveillance, Community Heart Failure
questionnaire

Chronic kidney disease (CKD)/
Dialysis / Renal transplantation
Amputation/diabetes retinopathy
Procedures, Revascularization,
Hospitalization

Medical records of
documented events or
procedures, serum urea and
creatinine and albumin for
CKD

Initiative for Cardiovascular Health
Research in the developing countries
(IC-Health) macroeconomic study
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Table 2 Summary of the surveillance indicators, measures, methods and instruments (Continued)
Treatment history,
health services,
quality of care and
health care costs**

Awareness and risk factor control

Questionnaire

IC-Health macroeconomic study

Access to health care services
Utilization of services
Health insurance / coverage
Costs of treating CMDs and their
risk factors

Chronic
Obstructive
Pulmonary
Disease (COPD),
Asthma*

Prevalence of COPD & asthma in
the population

Questionnaire

NHANES III and the present standards of
the American Thoracic Society (ATS)

Family history*

Prevalence of CMDs and their risk
factors in members of the family
related to the participants

Questionnaire

Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial

Mortality***

All cause

Follow-up surveys;
Death Certificates;
Verbal Autopsy

Modified version of Registrar General of
India – Center for Global Health Research
(RGI-CGHR) Prospective Study on Million
Deaths (Form 10C)

Cardiovascular disease specific;
Diabetes-specific

*Only cross-sectional surveys; **both cross-sectional survey and cohort follow-up; ***only cohort follow-up.

Surveillance indicators and study instruments

To provide consistency and reproducibility of the results
across multiple sites, comprehensive and uniform data
collection instruments were used to capture measurements (Table 2). Household data were collected through
interviewer administered paper questionnaires in English
or the preferred local languages (Hindi, Tamil, and
Urdu). Validated questions were derived from English
questionnaires used in the WHO Multinational MONItoring of trends and determinants in CArdiovascular disease (MONICA) study [40], WHO STEPS studies [35],
and from previous regional and national surveys. Using
these, culturally-appropriate and methodologicallyrelevant closed-questions, an instrument for South-Asia
was developed and pilot tested for face and construct
validity prior to use in the study. Several sections of the
baseline questionnaire (such as the QoL, CMD history,
tobacco and alcohol consumption questions) were based
on validated questionnaires that already exist in regional
languages (Tamil, Hindi and Urdu). Questionnaires to
elicit medical and treatment history, costs and QoL are
being used to collect incident events during the ongoing
cohort follow-up. Further, verbal autopsy is being performed using a reliable instrument to ascertain cause of
death of participants who die during the course of
follow-up and for whom either death certificate was unavailable or cause of death not certified. For the adapted
instruments collecting a variety of CMD risks and diseases (e.g. tobacco, history of CMD, heart failure, and
Chronic Obstructive Pulmonary Disease), the subjective
history provided by participants was validated against laboratory and other diagnostic gold standards (e.g., salivary cotinine for tobacco consumption). These in-built

steps to validate the self-reported data distinguishes the
CARRS-Surveillance as a stronger model compared to
the IDSP [31] and the INDEPTH network (International
Network of field sites for continuous Demographic
Evaluation of Populations and Their Health in developing countries (www.indepth-network.org) [41].
Biological sample collection and storage

Biological sample collection involved drawing 15 ml of
blood (in fasting state) from each participant, collecting
urine (early morning void), and 1000 to 2000 μl of saliva
(fasting) in Salivettes. While blood and urine were collected from all participants, saliva was collected from 5%
of the study participants (i.e. 200 participants per site).
The samples were transported from field sites in cold
chain to the laboratories for analysis. Sample aliquots
were also stored in cryo-vials at - 80 degrees Celsius for
future studies. The methods of analysis and external
quality control have been standardised for all biological
samples across the study sites (Table 3). There is one exception in that Apolipoprotein A and B analyses were
not conducted in Karachi due to lack of required laboratory facilities for the test.
Clinical and anthropometric assessments

Two clinical (BP and pulse rate) and eight anthropometric measurements of participants were taken during the
visits: Clinical measurements - BP and Pulse rate. Anthropometric measurements - Mid-arm circumference,
Waist circumference, Hip circumference, Triceps skinfold, Sub-scapular skin-fold, Supra-patellar skin-fold,
Height (Standing) and Body composition analysis by
Bio-impedance.
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Table 3 Biological samples and their methods of analysis
Clinical
parameter

Laboratory parameter

Diabetes

Dyslipidemia

Kidney disease

Tobacco exposure

Methods used for analysis
Chennai

Delhi

Karachi

Fasting plasma glucose

Hexokinase/Kinetic

Hexokinase/Kinetic

Glucose Oxidase / End Point

Glycated haemoglobin
(HbA1c)

High performance liquid
chromatography (HPLC)

HPLC

HPLC

Total cholesterol

Cholesterol Oxidase Peroxidase
(CHOD-POD) end point

CHOD-POD end point

Enzymatic Colorimetric
method (CHOD-PAP)

High density lipoprotein
cholesterol

Direct

Direct

Direct

Low density lipoprotein
cholesterol

Friedwald Formula

Friedwald Formula

Friedwald Formula

Very low density lipoprotein
cholesterol

Calculation

Calculation

Calculation

Triglycerides

Enzymatic methods (GPO-PAP
end point)

Enzymatic methods
(GPO-PAP end point)

Enzymatic methods
(GPO-PAP end point)

Apolipoprotein A,
Apolipoprotein B

Immuno-turbidimetric

Immuno-turbidimetric

Will not be done

Serum urea

Urease Glutamate Dehydrogenase
(GLDH) / Kinetic

Urease GLDH/ Kinetic

Blood Urea Nitrogen (BUN):
Enzymatic conductivity rate
method

Serum creatinine

Jaffe Kinetic

Jaffe Kinetic

Modified Jaffe’s Method

Microalbuminuria

Immuno-turbidimetry

Immuno-turbidimetry

Rate nephelometry

Salivary cotinine

Elisa kit

Elisa kit

Elisa kit

The equipment and methods used for BP and anthropometric measurements were standardised and certified, and have been used in other epidemiological
studies in the South-Asian population. BP was measured
using electronic sphygmomanometer; Omron HEM7080 and HEM-7080IT-E; Omron Corporation, Tokyo,
Japan (certified by the British Hypertensive Society and
the American association for Advancement of Medical
Instrumentation [AAMI] protocols). Skinfold Calipers
(Holtain Ltd., UK) and non-stretch measuring tape
(Gulick II, Country Technology, Gays Mills, WI) were
used to measure skin-fold thickness and body circumferences, respectively. Height was measured using a portable
Stadiometer (SECA Model 213, SecaGmbh Co, Hamburg,
Germany). Apart from these, body-composition analysers
(instrument which measures body fat by sending out
weak electric currents to measure impedance/electrical
resistance by different tissues of the body); Tanita BC-418
in Delhi and Chennai, and BC-545 in Karachi were used
to measure compartmental body fat distribution. To ensure standardisation, both instruments were tested in 50
male and 50 female participants to compare the parameters measured; i.e. weight, body mass index, basal
metabolic rate, body fat and visceral fat. The results
showed that all measured parameters were highly corelated for both males and females (r > 0.95, p < 0.05) between the two instruments, except body fat in males
(r = 0.67, p = 0.67). Methods for BP measurement and

anthropometric measures were based on the recommendation of the American Heart Association’s Council on
High Blood Pressure Research [42] and the third National Health and Nutrition Examination Survey
(NHANES-III) [43].
Data management

An online system was developed in an ‘open source’
platform PHP (Hypertext PreProcessor, scripting language for the web page/front end) and MySQL (My
Structured Query Language) for data entry and database
management at each site. This online database has been
programmed to have automated in-built checks for logic
which are ‘clinically reasonable’ (such as ranges, absolute
and relative values, context and structure). It provides
an efficient means of data entry, storage, and quality
control. Data are available at the coordinating site for
immediate feedback and timely corrections. The data
have been stored in pass-word protected files and questionnaires in locked cabinets in all study sites, and only
the study personnel have access to these. All information
related to participant identification was de-linked from
the data files before analysis to maintain anonymity.
Quality control strategies

Quality control (QC) strategies were applied using a
framework which comprehensively considers each phase
of the study and applies inter-related themes to every
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Table 4 Quality assurance strategies
Levels of
quality control

Phases
Design and planning
● Critical review of protocols

Coordinating
center

● Common manual of operations for
three study sites

Pilot testing

Data collection

Data analysis

● Fluidity and feasibility
of field operations
assessed

● Monitoring field
activities

● Audit and evaluate
validity of findings prior
to publication
● Internal peer reviews
prior to publication

● Coordination of timelines & activities
Investigators

● Reviewed the design and planning of
the study
● Regular steering committee meetings

Field Personnel ● Extensive training over a period of 7–
10 days – theory and practical, field visits
and shadowing by the study managers

● Results were audited
after completion of the
pilot

● Monitoring

● Evaluated all field and
documenting techniques

● Random checks,
re-training

● Established clarity and
face validity in small field
sample

● Regular checks done
to assess completeness

● Evaluated calibration
techniques, acceptability
of use in field

● Regular calibration of
equipment; faulty
equipment replaced as
and when required

● Validity checks
● Results reviewed

● Easy-to-carry operations guide provided
Survey
Questionnaires

● Peer-reviewed
● Translated into local languages
● Internal consistency estimates and
reliability exercises through review of
literature on survey instruments and their
published data

Measuring
Equipment

● Centrally procured
● Central training
● Calibration guidelines and checks
developed

Specimens

● Kits and equipment procured centrally
● Specific protocols for each biochemical
assay was developed
● Extensive training (labeling, handling,
storage)

Laboratory

● Laboratory selected and reference
laboratory identified based on National
Accreditation Board for Testing and
Calibration Laboratories, Department of
Science and Technology, Government of
India (NABL) or College of American
Pathologists, Northfield, IL, USA(CAP)
certification

● Evaluated adherence to
protocols, labeling,
processing, storage and
handling
● Interim analysis conducted
to detect outliers
● Evaluated procedural
fluidity
● Evaluated intra- and
inter-laboratory variability

● Compromised or
inadequately completed
questionnaires identify
and discard

● Random checks done ● Samples stored for
future investigation

● External temperature
gauge labels to monitor
sample temperature

● Compromised samples
identify and discard

● Internal quality checks Assessment of intra- and
and calibration
inter-laboratory
coefficients of variation
●Regular external
validation – lyophilized
samples from reference
laboratory

● Analysis conducted to
● Internal and external quality assessment detect outliers
protocols and schedule of regularity
developed
Communication ● Reporting structures were established
● Data transfer planned
Documentation ● Checklists and logbooks were
maintained

● Agility of transfers
assessed
● Recording legibility
assessed

● Audit logbooks for
response rates and field
activity indicators
maintained

Training in appropriate and legible
documentation
Data Storage &
Confidentiality

● Data back-up and protection policies
have been established

● Accessibility, simplicity
and flexibility of software
assessed

● Training of all staff
Data Entry

● Protocols, consistent data cleaning
methods and verification systems were
established

● Locked and
password-protected
data storage
● Active back-up

● Variability assessments
conducted

● Datasets de-identified
● Access to personal
identifiers limited

● Reporting on outliers
● Interim analyses to
identify duplicate entries
● Validity checks
● Decision log to
● Database errors
document issues
tracked
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level of the study and are described in table 4. Apart
from standardisation of laboratory methods (Table 3),
QC involved laboratory procedure assessment at two
levels. Level-1, internal quality control: Local laboratories attached with the study centre followed their own internal quality control standard operating procedures
(SOPs) to ensure accuracy, precision, and reproducibility. Level-2; external quality control: Irrespective of the
nature of existing laboratory accreditation and / or
SOP’s, all study site laboratories were enrolled into an
external quality assessment program for clinical chemistry, HbA1c (glycated haemoglobin), lipid and human
urine. This was implemented with support from the
Randox International Quality Assurance Scheme
(RIQAS), UK. The frequency of external quality control
sample was two per month for clinical chemistry, lipid
and urine, and one per month for HbA1c.

Results
The first cross-sectional study was conducted between
September 2010 and November 2011. A total of 14, 215
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individuals in 8, 115 households were approached in the
three study sites (5348 participants in Chennai, 4609 in
Delhi, and 4258 in Karachi). From these, a total of
13,384 participants were recruited (4943 Chennai, 4425
Delhi, and 4016 Karachi). A total of 831 eligible participants in the three sites refused to participate in the
study; overall response rate thus was 94.1% at the participant level (Chennai 92.4%, Delhi 95.7%, Karachi
94.3%). About eighty-one percent of the participants
recruited into the study contributed biospecimens
(Chennai 83.9%, Delhi 79.8% and Karachi 87.2%). Overall, 51.8% of the participants were females; a large proportion of the sample, 61.6% was below the age of
45 years, 27.5% in the 45–60 years age group and
10.9% > 60 years of age. In addition, the study provides
an understanding of the existing political and social
challenges in establishing a sustainable surveillance system for CMDs in the two countries and evidences of
context specific successful measures that can be adopted
to overcome most of these challenges (summarised in
Table 5).

Table 5 Challenges in the implementation of the study and methods used to overcome them
Mapping and listing of
households

Challenges

Solutions

Reference data Delhi and Chennai: 2001 census.
Karachi: 1998 census.

Complete listing of all the households in all randomly
selected CEBs was done by field workers and structural
maps of the areas were developed manually.

Lot of changes in structure and population had taken
place by 2010
Training of trainers (ToT) and
site managers for uniform
implementation of the study

Challenges with regards to organising the ToT in
either India or Pakistan due to visa issues for trainers
and participants.

The ToT was organised in Kathmandu, Nepal with
assistance from the Nepal Public Health Foundation.

Participant recruitment and
interviews

Poor response from upper socioeconomic status
localities and gated communities

Resident Welfare Association, Societies and Unions of
the localities were approached for cooperation.

Recruiting and interviewing male participants - who
could not be contacted on working days

Interviews were scheduled on weekends, early mornings
and late evenings, and more field workers were
recruited to conduct these weekend surveys.

Frequent electricity breakdowns in Karachi in the
evenings.

Emergency lights were arranged for interviewing the
participants in the evenings.

The socio-political climate in Karachi posed
challenges to the safety of interviewers and in
completion of surveys.

Field work was scheduled accordingly to target safe
areas as per the socio-political situation of the city on a
day-to-day basis.

Fear of providing blood samples among the
participants of lower socio economic status

Team leader and supervisor contacted and counselled
the participants.

Blood sample collection

Not coming fasting to the blood collection camps – The blood samples for these participants were not
some participants consumed tea or juices early in the collected in the camp on that day, but were collected
morning.
on another day from their homes ensuring that the
participant was in fasting state. The samples were
transported to the laboratory in appropriate cold chain.
Blood samples could not be collected during the
During the month of Ramadan, non-Muslim participants
month of Ramadan (Islamic fasting month) in Karachi. (mainly from the Christian communities) were recruited.

Anthropometry
Bio-impedance

Difficulty in conducting blood collection camps
during extreme (cold and hot) weather conditions.

As far as possible camps were avoided on extreme cold
and hot days in Delhi.

The instrument purchased for the other two sites
Tanita BC-418 was not available at Karachi and also
could not be shipped in to the country.

A different model of Tanita was used in Karachi, BC-554,
but the two models were compared by measuring the
correlation of their parameters in 100 participants
(described in the text).
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Discussion
The CARRS-Surveillance model has been established in
Chennai and New Delhi in India, and Karachi in
Pakistan with successful completion of the first crosssectional survey and initiation of the first year of cohort
follow-up. The response rate for the first cross-sectional
survey was more than 90% in all study sites with an
overall rate of 94%. The combined cross-sectional and
longitudinal study design lends it the advantages of:
(i) serial cross-sectional survey based models such as
the NHANES [43] and the Behaviour Risk Factor
Surveillance Surveys (BRFSS) in the USA [44] and
Jordan [45], and the national NCD risk factor
examination surveys in Seychelles [46] and Cuba
[47];
(ii) longitudinal prospective models such as the SCORE
(Systematic COronary Risk Evaluation) project
which helped to develop a risk scoring system for
management of CVD in Europe [48] and other
longitudinal studies which helped to estimate the
psychosocial risk factors of CHD [49].
CMDs are among the top ten most costly diseases
[50], but have the advantage of being largely predictable
through identification of distal and intermediate risk factors, and also substantially preventable through changes
in lifestyle and/or use of preventive pharmacology
[1,51,52]. The surveillance model if scaled up has the
potential to estimate secular trends and incidence rates
of mortality and morbidity due to CMDs, their complications and risk factors, thereby providing means of prioritizing and measuring the impact of public health
interventions.
In a recent review of prevailing methods of NCD surveillance, particularly of CVD in India, the authors reiterate the need for harmonising all existing efforts, at least
in measurement tools and quality assurance methods, to
establish an integrated, comprehensive, and standardised
surveillance system [53]. CARRS-Surveillance provides
an understanding of the challenges in establishing such a
surveillance system for CMDs, and elucidates the means
to address them. However, we suggest that such an effort
should not be limited to individual countries, but should
be consolidated for South-Asia as a whole because the
entire region is experiencing an epidemiological transition leading to increased incidence of CMDs and their
risk factors. Also, there are shared demographic, socioeconomic, behavioural, and physiological determinants
among South-Asians. One such multi-site collaborating
surveillance network is INDEPTH which regularly
collates cross-sectional survey data from 34 sites in
17 LMICs [41]. However, these are based on the selfselected samples of Health and Demographic Surveillance
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Systems (HDSS) in each site and are only representative
of a district, therefore, the findings cannot be generalised
to the region or the country [41].
Strengths and limitations

Apart from robust study methods and quality control
mechanisms, the sample population recruited in our
study conforms to the current age profile of the population in the two countries; about 65% of the population
in India and 75% of population in Pakistan are below the
age of 35 years [36,54]. This demonstrates the success of
the sampling strategy employed and has implications for
the generalisability of findings. However, a limitation of
the CARRS model is that the study setting is urban and
does not include the larger rural population where the
burden of CMD is also growing. An urban model, however, would anticipate the growth of urban areas the
world over, and also provide insights into operational
aspects of surveillance systems, and empirical evidence
of successful implementation at lower costs. The New
York City Health and Nutrition Examination Survey
(NYC HANES) provides an aspirational model suggesting that surveillance in such metropolitan cities with diverse populations might provide a reasonable reflection
of diverse and growing cities to each individual nation’s
disease burdens [55].
Several LMICs have some structure to estimate the
burden of NCDs, but a recent study by the WHO in
23 high burden countries (which includes India)
showed that the existing systems are deficient in standardised data collection tools and often lack accuracy
and quality [56]. The CARRS-Surveillance model
addresses these technical standardisation and quality
challenges in setting up national and regional CMD
surveillance systems in South-Asia, but the task of scaling up will require political commitment, funds, and
human resources. Although challenging, this is achievable and has been accomplished by a few LMICs. For
example, the Ministry of Health in Jordan, in partnership with WHO and CDC, established the Jordan
BRFSS in 2002 which conducts cross-sectional surveys
every two to three years [45]. The national examination
survey of NCD risk factors in Seychelles has been collecting data for planning and evaluating interventions
since 1989 [46], and the Cuban system since 1995–96
[47]. Eleven Latin American countries (Argentina, Brazil,
Chile, Colombia, Dominican Republic, Guatemala, Mexico,
Panama, Peru, Uruguay and Venezuela) have new or
emerging systems for serial national NCD and risk
factor surveys in various stages of development [57].
These countries have demonstrated the utility of continuous surveillance in identifying high risk communities, planning interventions, and evaluating the effects
of existing policies, thereby creating an evidence-base
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for steering national policies on NCD prevention and
health promotion [45-47,57].
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